<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33531377</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e953</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000953</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine whether neutrophils contribute to amyotrophic lateral sclerosis (ALS) progression, we tested the association of baseline neutrophil count on ALS survival, whether the effect was sex specific, and whether neutrophils accumulate in the spinal cord.</AbstractText><AbstractText Label="METHODS">A prospective cohort study was conducted between June 22, 2011, and October 30, 2019. Blood leukocytes were isolated from ALS participants and neutrophil levels assessed by flow cytometry. Participant survival outcomes were analyzed by groups (&lt;2 &#xd7; 10<sup>6</sup>, 2-4 &#xd7; 10<sup>6</sup>, and &gt;4 &#xd7; 10<sup>6</sup> neutrophils/mL) with adjustments for relevant ALS covariates and by sex. Neutrophil levels were assessed from CNS tissue from a subset of participants.</AbstractText><AbstractText Label="RESULTS">A total of 269 participants with ALS within 2 years of an ALS diagnosis were included. Participants with baseline neutrophil counts over 4 &#xd7; 10<sup>6</sup>/mL had a 2.1 times higher mortality rate than those with a neutrophil count lower than 2 &#xd7; 10<sup>6</sup>/mL (95% CI: 1.3-3.5, <i>p</i> = 0.004) when adjusting for age, sex, and other covariates. This effect was more pronounced in females, with a hazard ratio of 3.8 (95% CI: 1.8-8.2, <i>p</i> = 0.001) in the &gt;4 &#xd7; 10<sup>6</sup>/mL vs &lt;2 &#xd7; 10<sup>6</sup>/mL group. Furthermore, ALS participants (n = 8) had increased neutrophils in cervical (<i>p</i> = 0.049) and thoracic (<i>p</i> = 0.022) spinal cord segments compared with control participants (n = 8).</AbstractText><AbstractText Label="CONCLUSIONS">Higher neutrophil counts early in ALS associate with a shorter survival in female participants. Furthermore, neutrophils accumulate in ALS spinal cord supporting a pathophysiologic correlate. These data justify the consideration of immunity and sex for personalized therapeutic development in ALS.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE">This study provides Class III evidence that in female participants with ALS, higher baseline neutrophil counts are associated with shorter survival.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murdock</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-3543-4007</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor. sgoutman@med.umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boss</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5285-3038</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sehee</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1815-6957</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0002-9162-2694</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2C TR002818</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>3</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33531377</ArticleId><ArticleId IdType="pmc">PMC8057067</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000953</ArticleId><ArticleId IdType="pii">8/2/e953</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum (Minneap Minn) 2017;23:1332&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, et al. . Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Asselain B, Guillet P, et al. . Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 2006;66:88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL. The dual roles of immunity in ALS: injury overrides protection. Neurobiol Dis 2015;77:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 2013;8:888&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Kashlan SR, et al. . Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2016;3:e242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol 2017;74:1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Hong YH, Kim SM, Shin JY, Suh YJ, Sung JJ. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis. Sci Rep 2020;10:428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965090</ArticleId><ArticleId IdType="pubmed">31949271</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, et al. . The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler 2010;11:439&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:907&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Su FC, Goutman SA, Chernyak S, et al. . Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol 2016;73:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Kim S, Qin J, Saran R, Li Y. A pairwise likelihood augmented Cox estimator for left-truncated data. Biometrics 2018;74:100&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402872</ArticleId><ArticleId IdType="pubmed">28853158</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimujiang A, Wiensch A, Boss J, et al. . Association between life purpose and mortality among US adults older than 50 years. JAMA Netw Open 2019;2:e194270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632139</ArticleId><ArticleId IdType="pubmed">31125099</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Crowson CS, Atkinson EJ. Adjusted survival curves. 2015.</Citation></Reference><Reference><Citation>Figueroa-Romero C, Guo K, Murdock BJ, et al. . Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice. Dis Model Mech 2019;13:dmm041947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6906635</ArticleId><ArticleId IdType="pubmed">31597644</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, McCombe PA, Henderson RD, et al. . Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun 2020;2:fcaa013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim CF, Moalem-Taylor G. Detailed characterization of neuro-immune responses following neuropathic injury in mice. Brain Res 2011;1405:95&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21741621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation 2014;11:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174328</ArticleId><ArticleId IdType="pubmed">25163400</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach K, Piedavent M, Bauer S, Neumann JT, Friese MA. Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J Immunol 2013;191:4531&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">24062488</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaw YM, Cunningham C, Tierney A, Sivaguru M, Inoue M. Neutrophil-selective deletion of Cxcr2 protects against CNS neurodegeneration in a mouse model of multiple sclerosis. J Neuroinflammation 2020;17:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7001284</ArticleId><ArticleId IdType="pubmed">32019585</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, Moumen A, Sazdovitch V, Seilhean D, Meininger V, Raoul C. Elevated levels of IFNgamma and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Eur J Neurol 2012;19:752&#x2013;759, e745&#x2013;e756.</Citation><ArticleIdList><ArticleId IdType="pubmed">22221541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, Baiocchi C, Bongioanni P, et al. . TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol 2008;194:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, et al. . Interleukin-15 and interleukin-12 are elevated in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur Neurol 2010;63:285&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">20407265</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int Immunol 2015;27:117&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff TM, Costantini KJ, Crane JW, et al. . The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 2008;181:8727&#x2013;8734.</Citation><ArticleIdList><ArticleId IdType="pubmed">19050293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG. Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2018;15:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984816</ArticleId><ArticleId IdType="pubmed">29859100</ArticleId></ArticleIdList></Reference><Reference><Citation>Briones MRS, Snyder AM, Ferreira RC, Neely EB, Connor JR, Broach JR. A possible role for platelet-activating factor receptor in amyotrophic lateral sclerosis treatment. Front Neurol 2018;9:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810282</ArticleId><ArticleId IdType="pubmed">29472887</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster RO, Hong SR, Johnston RB Jr, Henson PM. Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function. Immunopharmacology 1980;2:201&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">6254906</ArticleId></ArticleIdList></Reference><Reference><Citation>Khreiss T, Jozsef L, Chan JS, Filep JG. Activation of extracellular signal-regulated kinase couples platelet-activating factor-induced adhesion and delayed apoptosis of human neutrophils. Cell Signal 2004;16:801&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15115659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J, Zheng WF. Effect of sex hormones on NK and ADCC activity of mice. Int J Immunopharmacol 1988;10:15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3366506</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod 2008;78:432&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">18003947</ArticleId></ArticleIdList></Reference><Reference><Citation>Potluri T, Fink AL, Sylvia KE, et al. . Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccin 2019;4:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626024</ArticleId><ArticleId IdType="pubmed">31312529</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Korchak HM, Rutherford LE, Ganguly M, Weissmann G. Female hormones reduce neutrophil responsiveness in vitro. Arthritis Rheum 1984;27:623&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">6329234</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller AP, Feng W, Xing D, et al. . Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004;110:1664&#x2013;1669.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353495</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin DP, Bolin AP, dos Santos Rde C, Curi R, Otton R. Testosterone suppresses oxidative stress in human neutrophils. Cell Biochem Funct 2010;28:394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">20589735</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa A, Gelosa P, Castiglioni L, et al. . Sex-specific features of microglia from adult mice. Cell Rep 2018;23:3501&#x2013;3511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024879</ArticleId><ArticleId IdType="pubmed">29924994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz KM, Nugent BM, Haliyur R, McCarthy MM. Microglia are essential to masculinization of brain and behavior. J Neurosci 2013;33:2761&#x2013;2772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727162</ArticleId><ArticleId IdType="pubmed">23407936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz KM, Wright CL, Martin RC, McCarthy MM. Prostaglandin E(2) regulates AMPA receptor phosphorylation and promotes membrane insertion in preoptic area neurons and glia during sexual differentiation. PLoS One 2011;6:e18500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072395</ArticleId><ArticleId IdType="pubmed">21490976</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield TA, Best TM, Merrick MA. The dual roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair. J Athl Train 2006;41:457&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748424</ArticleId><ArticleId IdType="pubmed">17273473</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, et al. . Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006;9:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau E, Di Polo A, Vande Velde C, Robitaille R. Sex-specific differences in motor-unit remodeling in a mouse model of ALS. eNeuro 2020;7:ENEURO.0388-19.2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7044502</ArticleId><ArticleId IdType="pubmed">32033983</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdani S, Mariosa D, Hammar N, et al. . Peripheral immune biomarkers and neurodegenerative diseases: a prospective cohort study with 20 years of follow-up. Ann Neurol 2019;86:913&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">31604369</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivner MH, Liu S, Quarles B, et al. . Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve 2017;55:430&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5318258</ArticleId><ArticleId IdType="pubmed">27756107</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et al. . Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>HEALEY ALS Platform
Trial&#x2014;Master Protocol. Available at: ClinicalTrials.gov/show/NCT04297683. Accessed May 19,
2020.</Citation></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. . Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019;92:e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillack K, Naegele M, Haueis C, et al. . Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J Neuroimmunol 2013;261:108&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">23735283</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng HJ, Nikolakopoulos S, et al. . Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451&#x2013;e460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, et al. . Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve 2020;62:156&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>